Subjects with pre-existing cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9804 overweight or obese subjects with pre-existing cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subitramine (4905 subjects) or a placebo (4899 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 561 subjects in the subitramine group and 495 subjects in the placebo group. Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome